Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05493618
Title Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.
Recruitment Withdrawn
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Hackensack Meridian Health
Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.